A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Ono Pharmaceutical Co., Ltd.
- Study ID
- NCT06948448
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ONO-4578 — DRUGONO-4578 tablets once a day
- Opdivo® — DRUGSpecified dose on specified days
- Oxaliplatin — DRUGSpecified dose on specified days
- 5-Fluorouracil — DRUGSpecified dose on specified days
- Bevacizumab — DRUGSpecified dose on specified days
- Leucovorin — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.
Key Dates
- Start date
- Nov 18, 2025
- Status verified
- May 2026
- Primary completion
- Feb 15, 2028
- Completion
- Oct 1, 2028
Study Design
- Enrollment
- 144 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A ONO-4578 dose 1 + Opdivo® + SOC (mFOLFOX6 + bevacizumab)
- Experimental: Arm B ONO-4578 dose 2 + Opdivo® + SOC (mFOLFOX6 + bevacizumab)
- Active Comparator: Arm C SOC (mFOLFOX6+bevacizumab)
Primary Outcome Measure
Overall Response Rate (ORR) per Blinded Independent Central Review (BICR) [ Time Frame: From randomization to the end of treatment (Up to 39 months) ]
Central Contacts
- North America Clinical Trial Support Desk+18665877745(Toll-Free)
- International Clinical Trial Support Desk+17162141777(Standard)
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | - |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | - |
| Rocky Mountain Cancer Centers, LLP | Lone Tree | Colorado | 80124 | - |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | - |
| Advent Health | Orlando | Florida | 32803 | - |
| May Clinic Rochester | Rochester | Minnesota | 55905 | - |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43221 | - |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | - |
| Baylor Scott & White Medical Center | Temple | Texas | 76508 | - |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | - |
| Blue Ridge Cancer Care | Salem | Virginia | 24153 | - |
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- ColoCare Study - Colorectal Cancer CohortRecruiting · University of Utah · Los Angeles, California
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesPHASE1/PHASE2 · Recruiting · Anwaar Saeed · Westwood, Kansas
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas